Retrospective observational study of osimertinib and afatinib for patients with advanced EGFR-mutated non-small cell lung cancer.
Not Applicable
- Conditions
- Advanced non-small cell lung cancer harboring EGFR mutation.
- Registration Number
- JPRN-UMIN000041251
- Lead Sponsor
- Central Japan Lung Study Group (CJLSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 557
Inclusion Criteria
Not provided
Exclusion Criteria
1. Not recieved afatinib or osimertinib as a monotherapy. 2. Recieved chemotherapy or immunotherapy before monotherapy of afatinib/osimertinib as systemic treatment for advanced non-small cell lung cancer. 3. Cases identified as ineligible by investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method